SubsidieMeestersThe first universal and price-neutral insulin pen
GO-Pen ApS aims to refine and scale the UNIPEN, an affordable and refillable insulin injection system, to improve dosing accuracy for over 13 million people with diabetes.
Projectdetails
Introduction
The challenge for many people with diabetes (PwD) is that they don’t get the right dose of insulin at the right time. This can potentially lead to long-term health issues and even shorten their lifetime.
Current Situation
Today, this is an everyday challenge for more than 13 million people who still inject insulin with a 100-year-old outdated technology (syringes and needles) and cannot afford branded insulin and modern pens.
Innovation Overview
GO-Pen ApS developed the first affordable, safe, and sustainable insulin injection system that fits the unmet health needs of the world’s most resource-constrained population.
UNIPEN System
The UNIPEN system innovation relies on the possibility of refilling a disposable cartridge with any kind of insulin available. This results in a cost-competitive device compared to syringes, improving accuracy.
Future Plans
Now, with the support of the EIC-A funding, we intend to:
- Refine the design of the UNIPEN device.
- Demonstrate its design and clinical usability.
- Fine-tune the scale-up production.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 4.642.308 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- GO-PEN APSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Beta-cell recovery to counter diabetesDiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Sonophoresis smartpatch for pain-free, controllable, and wearable transdermal drug deliveryWearable SmartPatch is a needle-free drug delivery system using sonophoresis to safely deliver macromolecular drugs through the skin, adaptable to various treatments and skin types. | EIC Accelerator | € 2.499.999 | 2023 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
Beta-cell recovery to counter diabetes
DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.
Sonophoresis smartpatch for pain-free, controllable, and wearable transdermal drug delivery
Wearable SmartPatch is a needle-free drug delivery system using sonophoresis to safely deliver macromolecular drugs through the skin, adaptable to various treatments and skin types.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMSPRISMA aims to validate a novel, ultra-compact micropump for wearable insulin delivery, enhancing accuracy and efficiency to revolutionize diabetes treatment and enable multi-drug systems. | EIC Transition | € 2.499.838 | 2022 | Details |
Epinefrine Auto Injector innovationDit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Universal 3D printer bioink for Type 1 diabetes cell therapyUniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment. | ERC Proof of... | € 150.000 | 2024 | Details |
Haalbaarheid: innovatief insulinekoelapparaat voor dagelijks gebruikHet project onderzoekt de haalbaarheid van een innovatief insulinekoelapparaat om diabetici te ondersteunen in hun dagelijkse zelfzorg. | Mkb-innovati... | € 20.000 | 2024 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
MICRO-MECHANICAL PUMP FOR NEXT GENERATION INSULIN DELIVERY SYSTEMS
PRISMA aims to validate a novel, ultra-compact micropump for wearable insulin delivery, enhancing accuracy and efficiency to revolutionize diabetes treatment and enable multi-drug systems.
Epinefrine Auto Injector innovation
Dit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren.
Universal 3D printer bioink for Type 1 diabetes cell therapy
Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.
Haalbaarheid: innovatief insulinekoelapparaat voor dagelijks gebruik
Het project onderzoekt de haalbaarheid van een innovatief insulinekoelapparaat om diabetici te ondersteunen in hun dagelijkse zelfzorg.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.